

## MEDIA RELEASE

### Thomson Medical Group's 2022 Board to be highly diverse

- *3 new directors, Christina Teo, June Leong and Wan Nadiah, will expand female Board membership to a third*
- *Board will expand to 9 from 7 with 56% non-executive directors, 67% serving 3 years or less and over half below 50 years old*
- *Lim Wee Kiat, 28, to be CEO of Thomson X and Executive Director of TMG Board*

**Singapore, 1 December 2021** – Thomson Medical Group (TMG), a leading women and children healthcare group in Singapore and Malaysia, said today it is adding three new members to its Board in a move that will make it highly diverse by gender, age and experience.

The three directors are Christina Teo Tze Wei and June Leong Lai Ling, both of whom will be Non-executive and Independent Directors, and Wan Nadiah who will be an Executive Director. At the same time, TMG has appointed Lim Wee Kiat as CEO of Thomson X (TX), and redesignated him from Non-Executive to Executive Director of TMG.

All appointments and redesignation will take effect from 1 January 2022. The new appointments will expand the Board's membership from seven to nine, and follow the retirement of Director Freddie Heng at the Company's annual general meeting on 22 October 2021.

TMG said it regularly reviews its Board's size and composition to ensure appropriate balance of experience, competencies and knowledge. With the latest move, women will make up one-third of its 2022 Board; 55% of the Board will be below the age of 50, including Lim Wee Kiat who is 28; while 56% will comprise Non-Executive Directors. The Board will also become more renewing with 67% or six members serving three years or less, 22% between six and eight years, and one, more than nine years.

Mr Ng Ser Miang, Chairman of TMG, said: "I extend a warm welcome to Christina, June and Nadiah, whose investment and healthcare experiences will help TMG move up to the next level. The regional healthcare industry is seeing rising demand from Asia's growing middle class, and new technologies are improving outcomes and transforming the way healthcare is delivered. TMG's management will be well supported by the new directors' experience, knowledge and contacts.

“TMG’s Board will also be the most diverse it has ever been. I look forward to chairing a Board filled with a renewed vigour to help management stay agile and purposeful.”

Mr Ng added that he is delighted to have Lim Wee Kiat assume an executive role at TX, the digital arm of TMG. “As a Board member, Kiat has been very active in helping management chart the Group’s technology roadmap. I have no doubt that his start-up experience will help us stay nimble as we expand into HealthTech, the fastest growing vertical within the healthcare sector.”

As CEO of TX, Mr Lim will lead and drive new growth areas in healthtech solutions through synergistic partnerships and investment opportunities and will leverage on the Groups’ healthcare expertise and extensive hospital and clinics network. He was appointed to the TMG Board on 15 March 2019 and last re-elected on 22 October 2021.

Mr Lim started his career with Kestrel Capital Pte Ltd and was involved in various investments and merger and acquisition transactions. A tech entrepreneur, he has founded two tech startups and continues to be involved in emerging sectors such as healthcare technology, technology platforms, Esports and Web 3.0 projects. Mr Lim graduated from the University of New South Wales Australia with a Bachelor of Science in Psychology.

Among the new directors, Ms Teo is the Co-founder and CEO of Singapore-based start-up UCARE.AI, an award-winning artificial intelligence-powered technology enabler for health data and solutions with esteemed customers including Singapore’s Ministry of Health, Great Eastern Life Assurance and Parkway Pantai. She has over 20 years of experience in private equity, leveraged buyouts, and mergers and acquisitions, and was previously CEO of Catpital, Managing Director at L Capital Asia (LVMH), among other senior investment positions at Affinity Equity Partners and Deutsche Bank’s Strategic Investments Group. She graduated with a Master of Business Administration from Harvard Business School and a Bachelor of Business Administration (Finance), Honours, from the National University of Singapore.

Ms Leong is CEO of Alpha Goal International, a dedicated single-family office that invests in a variety of asset classes around the world. She has held senior positions at China International Capital Corporation in Singapore and Hong Kong, was Executive Director at Standard Chartered Bank Private Wealth Management, and Executive Director at Goldman Sachs. Ms Leong graduated with an MBA from Peking University and a BSc in Engineering with Management from King's College, London.

Ms Nadiah heads TMG's Malaysia operations in her capacity as Executive Director and Group CEO of TMC Life Sciences Berhad (TMCLS). She is also the CEO of Thomson Hospital Kota Damansara and an Independent Director of the Institute of Corporate Directors in Malaysia. At 37, she is the youngest person on this year's Forbes Asia's list of Power Businesswomen, which recognises 20 outstanding female business leaders in the Asia-Pacific region. She holds an MSc in Public Health (Nutrition) from The London School of Hygiene and Tropical Medicine and an *AB cum laude* in Biochemical Sciences from Harvard College.

-End-

### **About Thomson Medical Group Limited**

Listed on the Mainboard of the Singapore Exchange, Thomson Medical Group Limited (**SGX: A50**) is one of the leading listed healthcare players in the South-East Asian region with operations in Singapore and Malaysia.

Established in 1979, the Group's Thomson Medical Pte Ltd is one of the largest private provider of healthcare services for women and children in Singapore. It owns and operates the iconic Thomson Medical Centre and a network of specialist medical clinics and facilities providing outpatient women and children healthcare services and service offerings in diagnostic imaging, health screening, gynaecological oncology, dentistry, specialist dermatology, traditional Chinese medicine, musculoskeletal and sports medicine, medical aesthetics and counselling and specialised learning for children with learning difficulties.

The Group's operations in Malaysia under TMC Life Sciences Berhad is a multi-disciplinary healthcare company listed on Bursa Malaysia. It operates Thomson Hospital Kota Damansara, a tertiary hospital located in Kota Damansara, and the award-winning TMC Fertility Centre which is the industry leader in assisted reproduction in Malaysia. It also owns the proposed Thomson Iskandar Medical Hub, in Johor Bahru, Malaysia.

The Group also owns a prime 9.23 ha freehold waterfront land, strategically located in Johor Bahru's City Centre, with a proposed long-term plan to build an integrated healthcare city to meet the growing healthcare needs of the people in the region.

For more information, please visit: [www.thomsonmedical.com](http://www.thomsonmedical.com)

For media enquiries, kindly contact:

**Warren Wu**

Corporate Communications, Thomson Medical Group Limited

Tel: (+65) 6933 8263

Email: [warrenwu@thomsonmedical.com](mailto:warrenwu@thomsonmedical.com)

**Catherine Ong Associates**

Catherine Ong

Tel: +65 9697 0007

Email: [cath@catherineong.com](mailto:cath@catherineong.com)